178 related articles for article (PubMed ID: 32833983)
1. Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience.
De-la-Cruz-Ku G; Luyo M; Morante Z; Enriquez D; Möller MG; Chambergo-Michilot D; Flores L; Luque R; Saavedra A; Eyzaguirre-Sandoval ME; Luján-Peche MG; Noel N; Calderon H; Razuri C; Fuentes HA; Cotrina JM; Neciosup SP; Araujo J; Lema A; Pinto J; Gomez HL; Valcarcel B
PLoS One; 2020; 15(8):e0237811. PubMed ID: 32833983
[TBL] [Abstract][Full Text] [Related]
2. Lymph node ratio as best prognostic factor in triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy.
De la Cruz-Ku GA; Chambergo-Michilot D; Valcarcel B; Rebaza P; Möller M; Araujo JM; Enriquez D; Morante Z; Razuri C; Luque R; Saavedra A; Eyzaguirre E; Lujan M; Noel N; Pinto J; Cotrina J; Gomez H
Breast J; 2020 Sep; 26(9):1659-1666. PubMed ID: 32713113
[TBL] [Abstract][Full Text] [Related]
3. Obesity and survival in the neoadjuvant breast cancer setting: role of tumor subtype in an ethnically diverse population.
Liu YL; Saraf A; Catanese B; Lee SM; Zhang Y; Connolly EP; Kalinsky K
Breast Cancer Res Treat; 2018 Jan; 167(1):277-288. PubMed ID: 28948418
[TBL] [Abstract][Full Text] [Related]
4. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
[TBL] [Abstract][Full Text] [Related]
5. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
6. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer.
Hall C; Karhade M; Laubacher B; Anderson A; Kuerer H; DeSynder S; Lucci A
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S552-8. PubMed ID: 25968619
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
[No Abstract] [Full Text] [Related]
9. Triple Negative Breast Cancer: 10-Year Survival Update of The Applied Treatment Strategy in Kuwait.
Fayaz S; Demian GA; El-Sherify M; Eissa H; Aziz M; Abuzallouf S
Gulf J Oncolog; 2019 Jan; 1(29):53-59. PubMed ID: 30957764
[TBL] [Abstract][Full Text] [Related]
10. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
11. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Neoadjuvant
Philipovskiy A; Corral J; Dwivedi KA; Heydarian R; Gaur S
In Vivo; 2019; 33(4):1227-1234. PubMed ID: 31280213
[TBL] [Abstract][Full Text] [Related]
13. Breast-conserving surgery vs. total mastectomy in patients with triple negative breast cancer in early stages: A propensity score analysis.
De-la-Cruz-Ku G; Valcarcel B; Morante Z; Möller MG; Lizandro S; Rebaza LP; Enriquez D; Luque R; Luján-Peche MG; Eyzaguirre-Sandoval ME; Saavedra A; Razuri C; Pinto JA; Fuentes HA; Neciosup SP; Gomez HL
Breast Dis; 2020; 39(1):29-35. PubMed ID: 31903977
[TBL] [Abstract][Full Text] [Related]
14. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
15. Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience.
Piedra-Delgado L; Chambergo-Michilot D; Morante Z; Fairen C; Jerves-Coello F; Luque-Benavides R; Casas F; Bustamante E; Razuri-Bustamante C; Torres-Roman JS; Fuentes H; Gomez H; Narvaez-Rojas A; De la Cruz-Ku G; Araujo J
PLoS One; 2024; 19(2):e0293833. PubMed ID: 38300959
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a beneficial effect of adjuvant chemotherapy in patients with stage I triple-negative breast cancer: a population-based study using the SEER 18 database.
Du ZL; Wang Y; Wang DY; Zhang L; Bian ZM; Deng Y; Xu CS; Lin DC; Xie L; Jia Y; Gao JD; Zhang BL
Breast Cancer Res Treat; 2020 Sep; 183(2):429-438. PubMed ID: 32647940
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations.
Clifton K; Gutierrez-Barrera A; Ma J; Bassett R; Litton J; Kuerer H; Moulder S; Albarracin C; Hortobagyi G; Arun B
Breast Cancer Res Treat; 2018 Jul; 170(1):101-109. PubMed ID: 29470805
[TBL] [Abstract][Full Text] [Related]
18. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
[TBL] [Abstract][Full Text] [Related]
19. BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy.
Bouchalova K; Svoboda M; Kharaishvili G; Vrbkova J; Bouchal J; Trojanec R; Koudelakova V; Radova L; Cwiertka K; Hajduch M; Kolar Z
Tumour Biol; 2015 Jun; 36(6):4243-52. PubMed ID: 25616695
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients.
Urru SAM; Gallus S; Bosetti C; Moi T; Medda R; Sollai E; Murgia A; Sanges F; Pira G; Manca A; Palmas D; Floris M; Asunis AM; Atzori F; Carru C; D'Incalci M; Ghiani M; Marras V; Onnis D; Santona MC; Sarobba G; Valle E; Canu L; Cossu S; Bulfone A; Rocca PC; De Miglio MR; Orrù S
BMC Cancer; 2018 Jan; 18(1):56. PubMed ID: 29310602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
